Evidence map›Paper›PMID 25277305›Full record

Trial reportEye (London, England)2015

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.

C K Chan, P Abraham, D Sarraf, A S D Nuthi, S G Lin, C A McCannel

Registry-linked trialOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Eye (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02944227 (Efficacy of Fixed Monthly Dosing of Lucentis®), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02944227 phase4completednot on this mapstarted 2016, after this paper: background citation

Efficacy of Fixed Monthly Dosing of Lucentis® (Ranibizumab) on Subretinal Fluid (SRF) Associated With Persistent Pigment Epithelial Detachment (PED) in Neovascular Age-related Macular Degeneration (AMD): A Pilot Study

TypeinterventionalSponsorSeoul National University HospitalRan2016 to 2017Enrolled20ConditionsWet Macular DegenerationArmsLucentis
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. [Volumetric analysis of vascularized pigment epithelium detachment in AMD: post hoc analysis of the RECOVER study].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2018
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

C K Chan1] Southern California Desert Retina Consultants, Palm Desert, CA, USA [2] Loma Linda University, Department of Ophthalmology, Loma Linda, CA, USA.
P AbrahamBlack Hills Regional Eye Institute, Rapid City, SD, USA.
D SarrafRetinal Disorders and Ophthalmic Genetics, Jules Stein Eye Institute, UCLA, Los Angeles, CA, USA.
A S D NuthiSouthern California Desert Retina Consultants, Palm Desert, CA, USA.
S G LinSouthern California Desert Retina Consultants, Palm Desert, CA, USA.
C A McCannelRetinal Disorders and Ophthalmic Genetics, Jules Stein Eye Institute, UCLA, Los Angeles, CA, USA.
Southern California Desert Retina Consultants · USDoheny Eye Institute · USBlack Hills Regional Eye Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summary statementIntravitreal high dose (2 mg) ranibizumab may lead to quicker resolution of choroidal neovascularization (CNV) and associated retinal pigment epithelial detachment in eyes with exudative age-related macular degeneration, although it may possibly correlate with RPE tears in certain cases. PURPOSE: This prospective study compared the outcomes of 0.5 vs 2.0 mg intravitreal ranibizumab injections (RI) for treating vascularized pigment epithelial detachment (vPED) due to age-related macular degeneration.

methodsPatients with vPED were randomized to receive 2.0 vs 0.5 mg RI monthly for 12 months or for 4 months and then repeated on a pro-re nata basis. Optical coherence tomography, fundus photography, and fluorescein and indocyanine-green angiography were obtained at baseline and subsequent specific intervals. Outcome measures were best-corrected standardized visual acuities, central 1-mm thickness, surface area (SA), greatest linear diameter (GLD), heights (PED and CNV), and amount of subretinal fluid (SRF) and cystoid macular edema (CME).

resultsBoth groups yielded reductions of the central 1-mm thickness, PED and CNV SA and PED height and GLD, SRF, and CME. Vision improvement and reduction in SRF and PED height occurred earlier for eyes receiving the 2.0 mg dose. Cataract progression was similar but RPE tears developed more often with the 2.0 mg dose.

conclusionsThere were similar visual and anatomical outcomes at the end of the study; however, the higher dose yielded more rapid reductions and more complete resolution of the PED, although there was possible increased tendency for an RPE tear with the higher dose.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedColoring AgentsContrast SensitivityFemaleFluorescein AngiographyHumansIndocyanine GreenIntravitreal InjectionsMaleProspective StudiesRanibizumabRetinal DetachmentRetinal NeovascularizationAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedColoring AgentsIndocyanine GreenRanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID25277305
PMCPMC4289828
OpenAlexW2093090078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.